FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma
- DOI
- 10.1158/1078-0432.ccr-21-2334
- Published
- 2022-02-01
- Container
- Clinical Cancer Research
- Publisher
- American Association for Cancer Research (AACR)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1158/1078-0432.ccr-21-2334,
title = {FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma},
author = {Elaine Chang and Chana Weinstock and Lijun Zhang and Mallorie H. Fiero and Miao Zhao and Eias Zahalka and Tiffany K. Ricks and Jeanne Fourie Zirkelbach and Junshan Qiu and Jingyu Yu and Xiao Hong Chen and Vishal Bhatnagar and Kirsten B. Goldberg and Shenghui Tang and Paul G. Kluetz and Richard Pazdur and Amna Ibrahim and Julia A. Beaver and Laleh Amiri-Kordestani},
year = {2022},
journal = {Clinical Cancer Research},
doi = {10.1158/1078-0432.ccr-21-2334},
url = {https://doi.org/10.1158/1078-0432.ccr-21-2334}
}RIS
TY - JOUR TI - FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma AU - Elaine Chang AU - Chana Weinstock AU - Lijun Zhang AU - Mallorie H. Fiero AU - Miao Zhao AU - Eias Zahalka AU - Tiffany K. Ricks AU - Jeanne Fourie Zirkelbach AU - Junshan Qiu AU - Jingyu Yu AU - Xiao Hong Chen AU - Vishal Bhatnagar AU - Kirsten B. Goldberg AU - Shenghui Tang AU - Paul G. Kluetz AU - Richard Pazdur AU - Amna Ibrahim AU - Julia A. Beaver AU - Laleh Amiri-Kordestani PY - 2022 JO - Clinical Cancer Research DO - 10.1158/1078-0432.ccr-21-2334 UR - https://doi.org/10.1158/1078-0432.ccr-21-2334 ER -
APA
Chang, E., Weinstock, C., Zhang, L., Fiero, M. H., Zhao, M., Zahalka, E., Ricks, T. K., Zirkelbach, J. F., Qiu, J., Yu, J., Chen, X. H., Bhatnagar, V., Goldberg, K. B., Tang, S., Kluetz, P. G., Pazdur, R., Ibrahim, A., Beaver, J. A., & Amiri-Kordestani, L. (2022). FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-2334
Source records
- crossref · retrieved 2026-09-26T11:30:58.477Z